Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer

Next Previous
Trial Profile

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate Cancer

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talazoparib (Primary) ; Degarelix; Degarelix; Enzalutamide; Leuprorelin; Leuprorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions

Most Recent Events

  • 04 Mar 2025 Planned initiation date changed from 30 Sep 2024 to 30 Sep 2025.
  • 26 Feb 2024 Planned initiation date changed from 30 Sep 2023 to 30 Sep 2024.
  • 26 Jul 2023 Planned initiation date changed from 1 Jul 2023 to 30 Sep 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top